Caring
For
Life
Caring
For
Life
Caring
For
Life
“At Xeedia Pharmaceuticals, our commitment extends beyond business; it’s about making a meaningful impact on society, our environment, and sustainable growth.”
Dr. Amr Desoky, CEO
Milestones, achievements, and more in Xeedia’s 2025 highlights
Create effective change and impact on daily lives.
Join Xeedia in improving the health and well-being of patients in the MENA region through innovative, effective, and affordable solutions.
Xeedia’s participating with eminent Gynecologists in one of the most important conferences in Egypt
Proudly participating in ESC for the 6th consecutive year Launching Xeedia Beats, our scientific platform bringing the latest updates in cardiovascular disease management closer to Egyptian healthcare professionals.
Proud moments at Cardio Alex 2026 Celebrating Xeedia’s journey with the launch of Bendovaxeed 180 mg and Bendovaxeed Plus 180/10 mg, advancing lipid management
Xeedia contribution in one of the biggest Gynecologists conferences in Egypt with Omegal supplements portfolio
Xeedia continues to strengthen its presence in Egypt’s cardiology community, witnessing the Egyptian Heart House elections as part of its ongoing engagement with the cardiovascular field.
77th annual conference of the Egyptian orthopedic Association Sharing Diclopro Portfolio with our eminent Professors of Orthopedics
Five years of success, dedication, faith, and a shared commitment to improving patients’ lives.. Celebrating Zyrovazet’s sustained market leadership by value in the statin market, made possible by the trust of Egypt’s most eminent cardiologists and diabetologists who have been part of our journey.
Xeedia continues to expand its role in diabetes management with Linagliflozin, participating in one of Egypt’s leading diabetes conferences and reinforcing its commitment to advancing patient care.
Always present, always committed to science From Madrid, Xeedia continued its scientific journey, staying up to date with the latest guidelines alongside the eminent CVREP and EGSC boards.
Proudly contributing to science at Cardio Alex 2025 Launching ZEOS, our scientific study on Zyrovazet 10/40 efficacy and safety, building on Xeedia’s pioneering role as the first to launch this combination in Egypt.
Dr. Amr Desouky presented the role of national companies in providing high-quality medications that fill the gaps in the journeys of cardiac patients. He demonstrated Xeedia’s breakthrough product (Zyrovazet 10/40) and its high efficacy in the secondary prevention of cardiovascular disease, filling a huge gap in Dyslipidemia management and making Xeedia’s participation a significant one.
Xeedia’s presence at The European Society of Cardiology (ESC) was a memorable one. We had the chance to join more than 300 Egyptian cardiologists in one of the most important events of the year for everything new in the guidelines and emerging therapies in managing cardiac patients. On the [date], we connected with the most prominent figures in the field and shared valuable insights.
Newsletter
